SPOTLIGHT: No new PML cases for Tysabri

As of September, there have been no new cases of the potentially fatal brain disease PML among patients taking Tysabri. The drug was pulled from the market last year after several patients taking the MS treatment developed PML. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.